Potentiation of anticancer-drug cytotoxicity by sea anemone pore-forming proteins in human glioblastoma cells

Anti-Cancer Drugs

Volumn 19, Issue 5, 2008, Pages 517-525

  Soletti, Rossana C ^a   De Faria, Giselle Pinto ^a   Vernal, Javier ^b   Terenzi, Hernán ^b   Anderluh, Gregor ^c   Borges, Helena L ^a   Moura Neto, Vivaldo ^a   Gabilan, Nelson H ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Anticancer drugs; Chemotherapeutic drugs; Cytolysins; Gliomas; Pore forming proteins

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DOXORUBICIN; EQUINATOXIN; PROTEIN P53; SEA ANEMONE TOXIN; TOXIN BC2; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG RESEARCH; GLIOBLASTOMA; HUMAN; HUMAN CELL; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT; SEA ANEMONE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CNIDARIAN VENOMS; CYTARABINE; DOXORUBICIN; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; PORE FORMING CYTOTOXIC PROTEINS; SEA ANEMONES; VINCRISTINE;

EID: 42349092876     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282faa704     Document Type: Article

References (37)

1. Kleihues P, Louis DN, Scheitauer BW, Rorke LB, Reinfenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61:215-225.
2. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 2004; 5:430-446.
3. Searcey M, Patterson LH. Resistance in cancer: a target for drug discovery. Curr Med Chem Anticancer Agents 2004; 4:457-460.
4. Panchal RG. Novel therapeutic strategies to selectively kill cancer cells. Biochem Pharmacol 1998; 55:247-252.
5. Basso U, Ermani M, Vastola F, Brandes AA. Non-cytotoxic therapies for malignant gliomas. J Neurooncol 2002; 58:57-69.
6. Chiocca EA, Broaddus WC, Gillies GT, Visted T, Lamfers LM. Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology. J Neurooncol 2004; 69:101-117.
7. Ellerby HM, Lee S, Ellerby LM, Chen S, Kiyota T, del Rio G, et al. An artificially designed pore-forming protein with anti-tumor effects. J Biol Chem 2003; 278:35311-35316.
8. Tejuca M, Diaz I, Figueredo R, Roque L, Pazoz F, Martinez D, et al. Construction of an immunotoxin with the pore forming protein StI and ior C5, a monoclonal antibody against a colon cancer cell line. Int Immunopharmacol 2004; 4:731-744.
9. Potrich C, Tomazzolli R, Dalla Serra M, Anderluh G, Malovrh P, Macek P, et al. Cytotoxic activity of a tumor protease-activated pore-forming toxin. Bioconjugate Chem 2005; 16:369-376.
10. Panchal RG, Smart ML, Bowser DN, Williams DA, Petrou S. Pore-forming proteins and their application in biotechnology. Curr Pharm Biotechnol 2002; 3:99-115.
11. Yang WS, Park SO, Yoon AR, Yoo JY, Kim MK, Yun CO, Kim CW. Suicide cancer gene therapy using pore-forming toxin, streptolysin O. Mol Cancer Ther 2006; 5:1610-1619.
12. Parker MW, Feil SC. Pore-forming protein toxins: from structure to function. Prog Biophys Mol Biol 2005; 88:91-142.
13. Migues PV, Leal RB, Mantovani M, Nicolau M, Gabilan NH. Synaptosomal glutamate release induced by the fraction Bc2 from the venom of the sea anemone Bunodosoma caissarum. Neuroreport 1999; 10:67-70.
14. 2+ in chromaffin cells. J Biol Chem 2000; 275:37488-37495.
15. Anderluh G, Pungercar J, Strukelj B, Macek P, Gubensek P. Cloning, sequencing, and expression of equinatoxin II. Biochem Biophys Acta 1996; 220:437-442.
16. Anderluh G, Macek P. Cytolytic peptide and protein toxins from sea anemones (Anthozoa: Actiniaria). Toxicon 2002; 40:111-124.
17. Anderluh G, Serra MD, Viero G, Guella G, Macek P, Menestrina G. Pore formation by equinatoxin II, a eukaryotic protein toxin, occurs by induction of nonlamellar structures. J Biol Chem 2003; 278:45216-45223.
18. De los Rios V, Mancheño JM, Lanio ME, Oñaderra M, Gavilanes JG. Mechanism of the leakage induced on lipid membranes by the hemolytic protein sticholysin II from the sea anemone Stichodactyla helianthus. Eur J Biochem 1998; 252:284-289.
19. Provoda CJ, Stier EM, Lee KD. Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin. J Biol Chem 2003; 278:35102-35108.
20. Provoda CJ, Lee KD. Bacterial pore-forming hemolysins and their use in the cytosolic delivery of macromolecules. Adv Drug Deliv Rev 2000; 41:209-221.
21. Trentin AG, Alvarez-Silva M, Moura Neto V. Thyroid hormone induces cerebellar astrocytes and C6 glioma cells to secrete mitogenic growth factors. Am J Physiol Endocrinol Metab 2001; 281:1088-1094.
22. Gomes FCA, Garcia-Abreu J, Galou M, Paulin D, Moura Neto V. Neurons induce GFAP gene promoter of cultured astrocytes from transgenic mice. Glia 1999; 26:97-108.
23. Gardner RS. A sensitive colorimetric assay for mitochondrial alpha glycerophosphate dehydrogenase. Anal Biochem 1974; 59:272-276.
24. Wolff JEA, Trilling T, Mölenkamp G, Egeler RM, Jürgens H. Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol 1999; 125:481-486.
25. Gondran M, Eckeli AL, Migues PV, Gabilan NH, Rodrigues AL. The crude extract from the sea anemone, Bunodosoma caissarum elicits convulsion in mice: possible involvement of the glutamatergic system. Toxicon 2002; 40:1667-1674.
26. Marmont AM. Selective metaphasic arrest of erythroblasts by vincristine in patients receiving high doses of recombinant human erythropoietin for myelosuppressive anemia. Leukemia 1992; 6:167-170.
27. Horton JK, Houghton PJ, Houghton PA. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol 1988; 15:3995-4000.
28. Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007; 67:9356-9363.
29. Van Mei EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, et al. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 1994; 54:649-652.
30. Lavie Y, Liscovitch M. Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconj J 2000; 17:253-259.
31. Alegre-Cebollada J, Rodriguez-Crespo I, Gavilanes JG, del Pozo AM. Detergent-resistant membranes are platforms for actinoporin pore-forming activity on intact cells. FEBS J 2006; 273:863-871.
32. Zhigaltsev IV, Maurer N, Akhong OF, Leone R, Leng E, Wang J, et al. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release 2005; 104:103-111.
33. Stringaris AK, Geisenhainer J, Bergmann F, Balshusemann C, Lee U, Zysk G, et al. Neurotoxicity of pneumolysin, a major pneumococcal virulence factor, involves calcium influx and depends on activation of p38 mitogen-activated protein kinase. Neurobiol Dis 2002; 11:355-368.
34. Stassen M, Muller C, Richter C, Neudorfl C, Hultner L, Bhakdi S, et al. Infect Immun. The streptococcal exotoxin streptolysin O activates mast cells to produce tumor necrosis factor alpha by p38 mitogen-activated protein kinase- dependent pathways and protein kinase C-dependent pathways. Infect Immun 2003; 71:6171-6177.
35. Husmann M, Dersch K, Bobkiewicz W, Beckmann E, Veerachato G, Bhakdi S. Differential role of p38 mitogen activated protein kinase for cellular recovery from attack by pore-forming S. aureus alpha-toxin or streptolysin O. Biochem Biophys Res Commun 2006; 344:1128-1134.
36. Casallanovo F, de Oliveira FJ, de Souza FC, Ros U, Martinez Y, Penton D, et al. Model peptides mimic the structure and function of the N-terminus of the pore-forming toxin Sticholysin II. Biopolymers 2006; 84:169-180.
37. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003; 65:3-13.